Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Monte Rosa Therapeutics, Inc. (GLUE : NSDQ)

• Company Description    Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON. Number of Employees: 93

• Price / Volume Information    Yesterday's Closing Price: $8.35 Daily Weekly Monthly 20 Day Moving Average: 155,712 shares Shares Outstanding: 46.67 (millions) Market Capitalization: $389.68 (millions) Beta: 52 Week High: $45.56 52 Week Low: $7.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -34.51% -26.25% 12 Week -43.08% -37.43% Year To Date -59.11% -51.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 645 SUMMER STREET SUITE 102 - BOSTON,MA 02210 USA ph: 617-949-2643 fax: - ir@monterosatx.com http://www.monterosatx.com

• General Corporate Information    Officers Markus Warmuth - Chief Executive Officer; President Ajim Tamboli - Chief Financial Officer Alexander Mayweg - Director Bradley J. Bolzon - Director Ali Behbahani - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61225M102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 46.67 Most Recent Split Date: (:1) Beta: Market Capitalization: $389.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.20 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -24.47 12/31/21 - -27.56 09/30/21 - - ROA 03/31/22 - -23.37 12/31/21 - -26.43 09/30/21 - - Current Ratio 03/31/22 - 25.65 12/31/21 - 20.96 09/30/21 - 29.08 Quick Ratio 03/31/22 - 25.65 12/31/21 - 20.96 09/30/21 - 29.08 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.98 12/31/21 - 7.47 09/30/21 - 7.96 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©